2021
Differential impact of abluminal groove‐filled biodegradable‐polymer sirolimus‐eluting stent versus durable‐polymer everolimus‐eluting stent on and off dual antiplatelet therapy
Saito Y, Wijns W, Baumbach A, Xu B, Kelbæk H, Zheng M, Morel M, Anderson R, Schächinger V, Lansky A, Investigators T. Differential impact of abluminal groove‐filled biodegradable‐polymer sirolimus‐eluting stent versus durable‐polymer everolimus‐eluting stent on and off dual antiplatelet therapy. Catheterization And Cardiovascular Interventions 2021, 99: 357-365. PMID: 33502809, DOI: 10.1002/ccd.29468.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsCoronary Artery DiseaseDrug-Eluting StentsEverolimusHumansPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPolymersSirolimusTreatment OutcomeConceptsDual antiplatelet therapyTarget lesion failureDrug-eluting stentsTarget vessel myocardial infarctionBiodegradable polymer drug-eluting stentsChronic coronary syndromeAcute coronary syndromeDAPT discontinuationVessel myocardial infarctionAntiplatelet therapyCoronary syndromeMyocardial infarctionDurable polymer drug-eluting stentsIschemia-driven target lesion revascularizationIschemic coronary artery diseaseTarget lesion revascularizationIschemia-driven revascularizationPercutaneous coronary interventionCoronary artery diseaseIschemic coronary diseaseComer studyLesion revascularizationDAPT durationLesion failurePrimary endpoint
2020
Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
Saito Y, Nazif T, Baumbach A, Tchétché D, Latib A, Kaple R, Forrest J, Prendergast B, Lansky A. Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. JAMA Cardiology 2020, 5: 92-101. PMID: 31721980, DOI: 10.1001/jamacardio.2019.4367.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementAdjunctive antithrombotic therapyDual antiplatelet therapyAntithrombotic therapyAntiplatelet therapyValve replacementAortic stenosisAortic stenosis (AS) undergoing transcatheter aortic valve replacementSevere symptomatic aortic stenosisSurgical aortic valve replacementGuideline-recommended regimenOral anticoagulant useSevere aortic stenosisSingle antiplatelet therapySymptomatic aortic stenosisPatient risk factorsOngoing clinical trialsRisk prediction modelMajor bleedingOral anticoagulationAnticoagulant useStroke riskTAVR proceduresThrombotic risk
2019
Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting: Factors associated with stent occlusion
Attaran RR, Ozdemir D, Lin IH, Mena-Hurtado C, Lansky A. Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting: Factors associated with stent occlusion. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2019, 7: 527-534. PMID: 31203859, DOI: 10.1016/j.jvsv.2019.01.058.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsEndovascular ProceduresFemaleHumansIliac VeinMaleMay-Thurner SyndromeMiddle AgedPlatelet Aggregation InhibitorsPostthrombotic SyndromeProsthesis DesignRecurrenceRetrospective StudiesStentsTime FactorsTreatment OutcomeVascular PatencyVena Cava, InferiorVenous ThrombosisConceptsAcute deep vein thrombosisPost-thrombotic syndromeDeep vein thrombosisMay-Thurner syndromeDuration of anticoagulationAntiplatelet therapyPatency ratesIliocaval stentingIpsilateral deep vein thrombosisIliocaval venous stentingPrimary patency rateStent patency ratesCommon femoral veinVariety of indicationsLarge teaching hospitalVein thrombosisVenous stentingRetrospective reviewDVT groupStent groupFemoral veinProcedural dataStent patencyStent occlusionTeaching hospital
2015
Morphological changes and clinical impact of unstable plaques within untreated segments of acute myocardial infarction patients during a 3-year follow-up
Souza CF, Doi H, Mintz GS, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie BR, Kellett MA, Xu K, Mehran R, Stone GW, Maehara A. Morphological changes and clinical impact of unstable plaques within untreated segments of acute myocardial infarction patients during a 3-year follow-up. Coronary Artery Disease 2015, 26: 469-475. PMID: 25919902, DOI: 10.1097/mca.0000000000000251.Peer-Reviewed Original ResearchMeSH KeywordsAgedCoronary Artery DiseaseCoronary VesselsFemaleHumansMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPlaque, AtheroscleroticPlatelet Aggregation InhibitorsPredictive Value of TestsProspective StudiesRisk FactorsRupture, SpontaneousStentsTime FactorsTreatment OutcomeUltrasonography, InterventionalWound HealingConceptsST-segment elevation myocardial infarctionPlaque ruptureIntravascular ultrasoundClinical eventsUnstable plaquesLumen compromiseUntreated segmentsAcute Myocardial Infarction trialLong-term clinical outcomesAcute myocardial infarction patientsBaseline intravascular ultrasoundOptimal systemic therapySerial IVUS analysisMyocardial Infarction trialElevation myocardial infarctionInfarct-related arteryMyocardial infarction patientsThree-year followAttenuated plaqueHarmonizing OutcomesNonculprit lesionsSTEMI patientsSystemic therapyClinical outcomesInfarction patientsWill this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents.
Grundeken MJ, Lansky A, Tanguay JF, Gershlick A, Baumbach A, Cuisset T. Will this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents. EuroIntervention 2015, 11: 364-5. PMID: 26196757, DOI: 10.4244/eijv11i3a71.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overDrug-Eluting StentsHumansMalePlatelet Aggregation InhibitorsTiclopidineTreatment Outcome
2014
Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial)
Goto K, Lansky AJ, Ng VG, Pietras C, Nargileci E, Mehran R, Parise H, Feit F, Ohman EM, White HD, Bertrand ME, Desmet W, Hamon M, Stone GW. Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). The American Journal Of Cardiology 2014, 114: 1638-1645. PMID: 25312637, DOI: 10.1016/j.amjcard.2014.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAnticoagulantsCoronary AngiographyCoronary Artery DiseaseFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPeptide FragmentsPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPrognosisRecombinant ProteinsSeverity of Illness IndexTreatment OutcomeConceptsPercutaneous coronary interventionAcute coronary syndromeType C lesionsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsC lesionsLesion complexityBivalirudin monotherapyComposite ischemiaCoronary syndromeCoronary interventionIschemic eventsMyocardial infarctionCardiology/American Heart Association classificationAdverse short-term prognosisAmerican Heart Association classificationAdverse ischemic eventsComposite ischemic eventsContemporary interventional therapyMajor bleeding complicationsMajor hemorrhagic complicationsShort-term prognosisAcute CatheterizationAntithrombotic regimensMajor bleedingSex‐based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONS‐AMI trial
Yu J, Mehran R, Grinfeld L, Xu K, Nikolsky E, Brodie BR, Witzenbichler B, Kornowski R, Dangas GD, Lansky AJ, Stone GW. Sex‐based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONS‐AMI trial. Catheterization And Cardiovascular Interventions 2014, 85: 359-368. PMID: 25115966, DOI: 10.1002/ccd.25630.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsChi-Square DistributionFemaleHealth Status DisparitiesHemorrhageHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionOdds RatioPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsProportional Hazards ModelsProspective StudiesRisk FactorsSex FactorsStentsTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPrimary percutaneous coronary interventionMajor bleedingFemale sexRisk of MACEST-segment elevation myocardial infarction (STEMI) managementGlycoprotein IIb/IIIa inhibitorsAcute Myocardial Infarction trialIIb/IIIa inhibitorsHr of onsetAdverse cardiac eventsMyocardial Infarction trialHigh-risk subsetPresence of comorbiditiesMyocardial infarction managementPercutaneous coronary interventionBare metal stentsSex-based disparitiesFurther dedicated studiesLong-term managementHarmonizing OutcomesCardiac eventsCoronary interventionIschemic eventsSymptom onsetEsc
Meier P, Lansky AJ, Baumbach A. Esc. Acta Cardiologica 2014, 69: 100-108. PMID: 24640527, DOI: 10.1080/ac.69.1.3011351.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeDeath, Sudden, CardiacElectrocardiographyHumansMonitoring, PhysiologicMyocardial InfarctionOutcome Assessment, Health CarePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsTime-to-TreatmentTomography, Optical CoherenceUltrasonography, InterventionalConceptsST-elevation myocardial infarctionAcute coronary syndromeCardiac arrestUnstable coronary artery plaqueRecent therapeutic progressElevation myocardial infarctionNovel antiplatelet agentsCoronary artery plaquesSudden cardiac arrestCommon underlying causeACS mortalityElevation infarctionCoronary syndromeUnstable anginaAntiplatelet agentsArtery plaquesMyocardial infarctionTherapeutic progressUnderlying causeInfarctionArrestAnginaCangrelorPrasugrelTicagrelor
2013
First-in-Human Evaluation of a Bioabsorbable Polymer–Coated Sirolimus-Eluting Stent Imaging and Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries)
Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W. First-in-Human Evaluation of a Bioabsorbable Polymer–Coated Sirolimus-Eluting Stent Imaging and Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries). JACC Cardiovascular Interventions 2013, 6: 1026-1034. PMID: 24055443, DOI: 10.1016/j.jcin.2013.05.013.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAdultAgedAged, 80 and overAngina, StableAngina, UnstableAustraliaBelgiumCardiovascular AgentsChromium AlloysCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary StenosisCoronary VesselsDrug Therapy, CombinationDrug-Eluting StentsFemaleHumansMaleMiddle AgedMyocardial InfarctionNeointimaNew ZealandPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPolymersProspective StudiesProsthesis DesignSeverity of Illness IndexSirolimusTime FactorsTomography, Optical CoherenceTreatment OutcomeUltrasonography, InterventionalConceptsStent late lumen lossLate lumen lossSirolimus-eluting stentsOptical coherence tomographyIntravascular ultrasoundMajor adverse cardiac eventsSymptomatic coronary artery diseaseCoherence tomographyComplete strut coverageNeointimal volume obstructionUnderwent repeat angiographyAdverse cardiac eventsDual antiplatelet therapyCoronary artery diseaseUnstable angina pectorisDrug-eluting stentsLong-term riskAntiplatelet therapyVolume obstructionCardiac eventsRepeat angiographyAdverse eventsAngina pectorisArtery diseaseI trialPredictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial.
Caixeta A, Lansky AJ, Mehran R, Brener SJ, Claessen B, Généreux P, Palmerini T, Witzenbichler B, Guagliumi G, Brodie BR, Dudek D, Fahy M, Dangas GD, Stone GW. Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial. EuroIntervention 2013, 9: 220-7. PMID: 23518872, DOI: 10.4244/eijv9i2a37.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAngioplasty, Balloon, CoronaryAntithrombinsChi-Square DistributionCoronary AngiographyCoronary CirculationFemaleHumansKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedMyocardial InfarctionOdds RatioPlatelet Aggregation InhibitorsPredictive Value of TestsProportional Hazards ModelsProspective StudiesRecovery of FunctionRisk FactorsTime FactorsTreatment OutcomeConceptsTIMI 3 flowFinal TIMI 3 flowHORIZONS-AMI trialAcute myocardial infarctionPrimary PCITIMI flowMyocardial infarctionGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsNormal TIMI flowThree-year mortalityMulticentre prospective studyPatient-related factorsBaseline TIMIAngiographic factorsPrimary angioplastyIndependent predictorsUnfractionated heparinProspective studyAnterior MIAnatomical factorsPatientsTIMICore labLesion lengthRelationship Between ST-Segment Recovery and Clinical Outcomes After Primary Percutaneous Coronary Intervention
Farkouh ME, Reiffel J, Dressler O, Nikolsky E, Parise H, Cristea E, Baran DA, Dizon J, Merab JP, Lansky AJ, Mehran R, Stone GW. Relationship Between ST-Segment Recovery and Clinical Outcomes After Primary Percutaneous Coronary Intervention. Circulation Cardiovascular Interventions 2013, 6: 216-223. PMID: 23652600, DOI: 10.1161/circinterventions.112.000142.Peer-Reviewed Original ResearchMeSH KeywordsAgedChi-Square DistributionCoronary AngiographyElectrocardiographyFemaleFibrinolytic AgentsHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsProportional Hazards ModelsRecovery of FunctionRisk FactorsStentsTime FactorsTreatment OutcomeConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionPrimary PCIMajor adverse cardiovascular eventsST-segment resolutionAdverse cardiovascular eventsIschemia-driven target vessel revascularizationComplete ST-segment resolutionTarget vessel revascularizationPercutaneous coronary interventionMyocardial infarctionCardiovascular eventsVessel revascularizationCoronary interventionIndependent predictorsDegree of STRBaseline ST-segment elevationAcute Myocardial Infarction trialLong-term prognostic valueLong-term cardiovascular mortalityLeft ventricular ejection fractionLong-term predictive valuePost-PCI electrocardiogramsMyocardial infarction (TIMI) flowMyocardial Infarction trial
2012
Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Yu J, Mehran R, Dangas GD, Claessen BE, Baber U, Xu K, Parise H, Fahy M, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wöhrle J, Dudek D, Weisz G, Stone GW. Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2012, 5: 1231-1238. PMID: 23257371, DOI: 10.1016/j.jcin.2012.07.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAspirinFemaleHumansMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPostoperative CareProspective StudiesStentsConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionLow-dose aspirinElevation myocardial infarctionHigh-dose aspirinPrimary PCIHORIZONS-AMI trialPercutaneous coronary interventionMyocardial infarctionMajor bleedingCoronary interventionIschemic target vessel revascularizationMajor adverse cardiovascular eventsCoronary artery bypass surgeryLong-term patient outcomesAdverse ischemic eventsAdverse cardiovascular eventsDose of aspirinTarget vessel revascularizationArtery bypass surgeryHistory of hypertensionPremature coronary diseaseLong-term outcomesIschemic benefitAspirin doseRefining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome
Boden WE, Lansky A, Angiolillo DJ. Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome. The American Journal Of Cardiology 2012, 111: 439-444. PMID: 23168289, DOI: 10.1016/j.amjcard.2012.10.018.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeContraindicationsHumansPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsRisk FactorsSecondary PreventionTreatment OutcomeConceptsAcute coronary syndromeDual antiplatelet therapyAntiplatelet therapyCoronary syndromeHigh-risk percutaneous coronary interventionUnmet needPotent platelet inhibitionChronic kidney diseaseComplex coronary anatomyFirst-line therapyHigh-risk patientsLow-risk patientsPercutaneous coronary interventionSubgroup of patientsPrevious revascularizationPharmacologic managementCoronary interventionRisk patientsDiabetes mellitusPlatelet inhibitionSuch patientsCoronary anatomyKidney diseaseTherapeutic optionsTreatment optionsOptimal duration of clopidogrel therapy: the shorter the longer?
Meier P, Lansky AJ. Optimal duration of clopidogrel therapy: the shorter the longer? European Heart Journal 2012, 34: 1705-1707. PMID: 23136400, DOI: 10.1093/eurheartj/ehs385.Peer-Reviewed Original ResearchCoronary Artery DiseaseDrug-Eluting StentsHumansPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsMid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing.
Saito S, Nakamura S, Fujii K, Nakamura M, Isshiki T, Hirayama H, Kikuchi T, Fujita H, Nonogi H, Mitsudo K, Kimura T, Igarashi K, Saito K, Lansky AJ, Stone GW, Honda Y, Waseda K, Fitzgerald PJ, Sudhir K. Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing. Journal Of Invasive Cardiology 2012, 24: 444-50. PMID: 22954564.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsDrug-eluting stentsSegment late lossJapan RegistryLate lossUS patientsEES groupPrimary endpointSingle-arm multicenter studySecond-generation drug-eluting stentsFirst-generation drug-eluting stentsLower late lossTarget vessel failureAdverse cardiac eventsMid-term resultsCardiac eventsPES groupMulticenter studyJapanese patientsNeointimal volumeApposition ratePatientsStudy aimClinical programs
2011
Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R. Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 1011-1019. PMID: 21939942, DOI: 10.1016/j.jcin.2011.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsChi-Square DistributionChronic DiseaseDrug-Eluting StentsEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansIsraelKaplan-Meier EstimateKidney DiseasesMaleMetalsMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsProspective StudiesProsthesis DesignRecombinant ProteinsRecurrenceRisk AssessmentRisk FactorsStentsStrokeThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionNet adverse cardiac eventsChronic kidney diseasePercutaneous coronary interventionTarget vessel revascularizationBare metal stentsDrug-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingBivalirudin monotherapyCoronary interventionKidney diseaseMyocardial infarctionRate of TVRIschemia-driven target vessel revascularizationNon-coronary artery bypassIIb/IIIa inhibitorsBenefit of bivalirudinDifferent antithrombotic strategiesAdverse cardiac eventsComposite of deathHigh rateImpact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial)
Goto K, Nikolsky E, Lansky AJ, Dangas G, Witzenbichler B, Parise H, Guagliumi G, Kornowski R, Claessen BE, Fahy M, Mehran R, Stone GW. Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2011, 108: 1387-1394. PMID: 21864816, DOI: 10.1016/j.amjcard.2011.06.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsCoronary AngiographyCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug UtilizationFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPyridinesRecombinant ProteinsSmokingStentsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionElevation myocardial infarctionPrimary percutaneous coronary interventionProbable stent thrombosisPercutaneous coronary interventionUnfractionated heparinStent thrombosisMajor bleedingMyocardial infarctionBivalirudin monotherapyCoronary interventionSmoking statusPaclitaxel-eluting stent implantationIIb/IIIa inhibitorsAlternative antithrombotic regimensHORIZONS-AMI trialOutcomes of patientsImpact of smokingPaclitaxel-eluting stentsBare metal stentsLate stent thrombosisAntithrombotic regimensIschemic eventsIndependent predictorsPredictors and Implications of Coronary Infarct Artery Patency at Initial Angiography in Patients With Acute Myocardial Infarction (from the CADILLAC and HORIZONS-AMI Trials)
Brener SJ, Mehran R, Brodie BR, Guagliumi G, Witzenbichler B, Cristea E, Xu K, Lansky AJ, Stone GW. Predictors and Implications of Coronary Infarct Artery Patency at Initial Angiography in Patients With Acute Myocardial Infarction (from the CADILLAC and HORIZONS-AMI Trials). The American Journal Of Cardiology 2011, 108: 918-923. PMID: 21764028, DOI: 10.1016/j.amjcard.2011.05.022.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCoronary AngiographyCoronary CirculationCoronary VesselsDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPredictive Value of TestsRegional Blood FlowVascular PatencyConceptsTIMI grade 3 flowGrade 3 flowFinal TIMI grade 3 flowST-segment elevation myocardial infarctionElevation myocardial infarctionIndependent predictorsMyocardial infarctionPre-percutaneous coronary intervention (PCI) thrombolysisMyocardial Infarction (TIMI) grade 3 flowAcute Myocardial Infarction trialExtensive coronary diseaseLate Angioplasty ComplicationsMyocardial Infarction trialInfarct artery patencyAcute myocardial infarctionSignificant independent predictorsHigh-risk characteristicsAngioplasty complicationsBaseline TIMIControlled AbciximabHarmonizing OutcomesInitial angiographyCause mortalityPrimary PCIArtery patencyResponse to Letters Regarding Article, “Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Substudy”
Lansky A, Goto K, Fahy M, Cristea E, Mehran R, Stone GW, Feit F, Ohman EM, Alexander KP, White HD, Bertrand ME, Desmet W, Hamon M. Response to Letters Regarding Article, “Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Substudy”. Circulation 2011, 123: e410-e411. PMID: 21648119, DOI: 10.1161/circulationaha.110.010306.Peer-Reviewed Original ResearchFrequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction
Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möeckel M, Stone GW. Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation 2011, 123: 1745-1756. PMID: 21482968, DOI: 10.1161/circulationaha.110.981688.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsClopidogrelCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug-Eluting StentsFemaleHeparinHirudinsHumansMaleMetalsMiddle AgedMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPredictive Value of TestsRecombinant ProteinsRisk FactorsTiclopidineTreatment OutcomeTubulin ModulatorsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionElevation myocardial infarctionPercutaneous coronary interventionBare metal stentsDrug-eluting stentsStent thrombosisCoronary interventionMyocardial infarctionMetal stentsBivalirudin monotherapyOnly bare-metal stentsAcute Myocardial Infarction trialIIb/IIIa inhibitorsClopidogrel loading dosePotent antiplatelet therapyProbable stent thrombosisAcute stent thrombosisMyocardial Infarction trialAcute myocardial infarctionAntithrombin therapyHarmonizing OutcomesAntiplatelet therapyIndependent predictors